This stock is no longer traded. It was delisted on July 21, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Iterum Therapeutics plc is a clinical-stage pharmaceutical company headquartered in Dublin, Ireland. The company focuses on developing differentiated anti-infectives to combat the global crisis of multi-drug resistant pathogens, aiming to improve outcomes for patients with serious and life-threatening infectious diseases. Its lead product, ORLYNVAH (oral sulopenem), is the first and only approved oral penem, indicated for treating uncomplicated urinary tract infections (uUTIs) caused by designated microorganisms such as Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibiotic options. Sulopenem, a novel penem anti-infective, demonstrates potent in vitro activity against a broad spectrum of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. Iterum is also advancing an intravenous formulation of sulopenem. Through these innovations, Iterum Therapeutics plc addresses critical unmet needs in the anti-infective market, particularly for infections where treatment options are scarce.
Website3 Dublin Landings
Dublin, D01 C4E0
Ireland
The latest articles about ITRM.
DUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on...
--Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at...
Expanded Market Access for ORLYNVAHTM...
Summary of Oct 23's posts. Generated by AI.
Summary of Mar 31's posts. Generated by AI.
Summary of Mar 31's posts. Generated by AI.
Investors talking about ITRM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.